(Bloomberg) Doctors and parents are looking to new drugs and vaccines on the horizon to prevent a lung virus that’s been filling pediatric emergency rooms earlier than usual this season. Trial results this month from Pfizer Inc.’s maternal vaccine for respiratory syncytial virus, or RSV, and a European regulatory win for Sanofi and AstraZeneca Plc’s antibody that prevents the disease for a whole season have set the stage for the drugmakers to vie for control over an RSV vaccine market that could reach $10 billion.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.